AstraZeneca Faces Regulatory Repercussions for Symbicort Advertisement Violations

AstraZeneca's advertising approach for its respiratory medication, Symbicort, faced significant scrutiny from the PMCPA in the UK. This was due to six breaches in marketing rules, emphasizing the pharmaceutical industry's commitment to patient safety.